TACR3 and neoplasm: Pal et al. demonstrated that NKB could target the endothelium via a multi-component mechanism to oppose vascular remodeling [37], and Wang et al. reported that NK-3R agonist analogues might be used as templates for the development of anti-tumor drugs [38].